Companies will advance research on early ovarian cancer detection diagnostic tests.
The NCI awarded Rules-Based Medicine (RBM) and Correlogic Systems an SBIR $1.15 million contract to further research on ovarian cancer diagnostic tests.
The grant includes two phases: a Phase I fast-track component and a Phase II option. RBM will develop and test quantitative, multiplexed immunoassays incorporating 19 additional analytes that the companies have identified as promising targets potentially capable of enhancing accuracy of ovarian cancer detection.
Correlogic will expand its existing analytic platform to determine the efficacy of incorporating these additional analytes into the existing assay. Upon completion, RBM will add the 19 assays to its automated RBM Human Multi-Analyte Profile platform, HumanMAP®.
